Obesity enhances prostate volume (PV) growth and attenuates PV reduction by dutasteride, according to a study.
Roberto L. Muller, MD, of Duke University Medical Center in Durham, N.C., and collaegues conducted a secondary analysis of the Reduction by Dutasteride of Prostate Cancer Events trial.
Of 8,122 participants, they analyzed 71.8% and 54.5% with complete two- and four-year PV data, respectively. In multivariable analysis, men on placebo with a body mass index (BMI) of 30 kg/m2 or higher versus less than 25 had enhanced PV growth from baseline (at two years: 17% vs. 10.7%; at four years: 29.4% vs. 20.1%), the researchers reported online ahead of print in European Urology. Men on dutasteride with a BMI of 30 or higher versus less than 25 had attenuated PV reduction from baseline (at two years: −14.3% vs. −18.5%; at four years: −13.2% vs. −19.3%) and higher likelihood of having no PV reduction.
“The obesity effect on dutasteride-treated men is likely a combination of dutasteride-driven PV reduction with obesity-driven PV growth rather than decreased dutasteride efficacy,” the authors concluded.